47 results about "Multiple sclerosis" patented technology

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

This invention provides a pharmaceutical product for the prevention and / or treatment of pain, particularly neuropathic pain associated with multiple sclerosis, containing compounds with P2X4 receptor antagonism, such as compounds represented by general formula (IH), or their salts, or their hydrates or solvates, as active ingredients.

The present invention pertains to a method or a pharmaceutical composition of new ovatodiolide derivative compounds, AR100-RA1-Cys and AR100-RA1-ST, which have shown unexpected effects in treating autoimmune diseases, characterized by hepatocellular inflammation, such as autoimmune hepatitis, diabetes mellitus type 1, Sjogren's syndrome, multiple sclerosis and psoriasis. Also provided are the synthetic processes for compound preparation.

This disclosure relates to compounds of formula I (wherein X and R1-R4, n and m have the meanings set forth herein) and pharmaceutically acceptable salts thereof. Compounds of formula I exhibit GPR183 antagonist activity and are therefore useful in the treatment or prevention of disorders, conditions or diseases for which GPR183 antagonists have been shown to be useful, such as chronic pain, e.g., osteoarthritis, chronic low back pain, neuropathic pain, and immune system disorders, e.g., inflammatory bowel diseases such as colitis and Crohn's disease, multiple sclerosis, rheumatoid arthritis, inflammatory lung diseases, e.g., asthma, and psoriasis. TIFF2026522963000085.tif2570

The present invention relates to methods for treating multiple sclerosis (MS) in a patient, and in some cases, the methods involve subcutaneously administering an anti-CD20 antibody to the patient at a dose of about 920 mg. Compositions, formulations, and articles with instructions for such uses are also included.

THERAPEUTIC COMPOUNDS The present invention relates to compounds of Formula (I) which act to attenuate or block the function of the GPR17 receptor (e.g. compounds which act as GPR17 antagonists), wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, X5, and X6 each have any one of the meanings defined herein. The present invention also relates to pharmaceutical compositions comprising the compounds of Formula (I), and to their use in the diseases in which GPR17 attenuation is beneficial, such as in the treatment of multiple sclerosis (MS).

This invention discloses a novel class of monoacylglycerol lipase (MAGL) small molecule inhibitors, as well as their pharmaceutically acceptable compositions, methods of preparation, and uses. The MAGL small molecule inhibitors are represented by formula (I), having the specific substituents and definitions described herein. The disclosed MAGL small molecule inhibitors exhibit excellent MAGL enzyme inhibitory activity. This invention includes these compounds or their pharmaceutically acceptable compositions for the treatment and / or prevention of MAGL-related conditions such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colorectal cancer lesions, ovarian cancer, neuropathic pain, chemotherapy-induced neuropathy, acute pain, chronic pain, and / or pain-related spasticity.

Various embodiments of the present application provide binding molecules for B-lymphocyte antigens (e.g., CD19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD19 and CD20). Embodiments of the present application also provide cells expressing such binding molecules, therapeutic compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigens (e.g., CD19 and CD20), including hematological cancers, autoimmune diseases (e.g., multiple sclerosis and systemic lupus erythematosus).

The present invention relates a process for preparing a compound of Formula XX wherein: R1 is hydrogen, optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, aralkyl, alkoxy, aryloxy, alkenyloxy or alkynyloxy; R2 is an N-containign heterocyclyl or heteroaryl; and Q is optionally substitued aryl or heteroaryl. Furthermore a compound of the present invention are useful in the treamtment of various inflammatory, autoimmune and allergic diseases, such as method of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoartluitis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the overexpression and over-activation of a matrix metalloproteinase using the compound.

A sterol-based compound of formula (I) for its use in preventing, ameliorating and / or treating a mitochondrial deficiency-related pathology chosen from the group consisting of autism, spinal cord injury, multiple sclerosis, epilepsy, migraine, alcohol-related mental pathologies, ataxia, neuropathies, smoking-related cerebral and pulmonary disorders, MERRF syndrome and NARP syndrome. A pharmaceutical composition comprising at least one compound of formula (I).

The present invention relates to a method for identifying a compound that modulates the C-terminal Src kinase (Csk) by modulating at least one of the following features: the expression, amount, stability, biological activity of the Csk protein, and / or the interaction of the Csk protein with the lymphocyte-specific tyrosine kinase (Lck) protein in a mammalian cell. The identified compound is particularly suitable for use in the prevention or treatment of an autoimmune disease, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), multiple sclerosis (MS), and type 1 diabetes (T1D), or an infection, such as a bacterial or viral infection, cancer, cardiovascular diseases, age-related diseases, and preferably for use in increasing cellular immunity against cancer cells.Further aspects of the invention relate to a screening method for screening for a compound and / or a pharmaceutical composition comprising the compound.

The present invention provides methods of treating and ameliorating symptoms of multiple sclerosis using an antibody or antigen-binding fragment thereof that specifically binds human CD19 (e.g., ocrelizumab).

A method for treating relapsing-remitting multiple sclerosis (RMS) using fenebrutinib, an inhibitor of Bruton's tyrosine kinase (BTK), is provided herein.

Described herein are methods, compositions, products, and processes that utilize bioceramics in traditional agricultural and hydroponic systems. The bioceramics are utilized in powder form, as films, as aerosols, as water based treatment systems, or in solid forms. The methods and bioceramic compositions described here are also used for growing a Cannabis plant. One or more cannabinoids within the plant can be used in therapeutic compositions for the treatment of glaucoma, AIDS wasting syndrome, neuropathic pain, cancer, multiple sclerosis, chemotherapy-induced nausea, and certain seizure disorders.

New use of 1-amino-3,5-dimethyladamantane hydrochloride in treating or preventing cognitive impairment, reducing microglia in the cortex and hippocampus, reducing neuron loss in the cortex and hippocampus, and ameliorating the mitochondrial dysfunction state. The cognitive impairment includes cognitive impairment in systemic lupus erythematosus, Parkinson's disease, lateral sclerosis, stroke, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, attention deficit hyperactivity disorder, sepsis-related encephalopathy, or mild cognitive disorder. The present application also provides a corresponding drug and a treatment or prevention method.

The present invention relates to a sustained-release fampridine composition with high flowability and moisture control which can be used to treat individuals affected with multiple sclerosis and a preparation process thereof.

The present application provides a sulfonated trisaccharide and a preparation method thereof, the compound has drug activity, and can treat pulmonary arterial hypertension, inflammatory bowel disease and multiple sclerosis.

This invention relates to a drug screening method for diseases closely related to label-free G protein-coupled receptors (GPCRs), specifically to a label-free cell screening model for the GPR183 receptor and the application of drugs prepared from it. The label-free cell screening model is a stable cell line CHO-K1-GPR183 that highly expresses the GPR183 receptor. The GPR183 receptor agonist compound N-demethylnuciferine was obtained through screening using the GPR183 cell screening model established in this invention. Current research indicates that the GPR183 receptor is closely related to the occurrence and development of neuroinflammatory / autoimmune diseases such as multiple sclerosis, colitis, type 1 diabetes, and arthritis, as well as cancer and metabolic diseases, thus providing potential lead compounds for drug development in these diseases.

Described herein are methods and compositions, for example a fixed dose oral composition, for treating a TYK2-mediated neuroinflammatory disease or disorder, and / or a TYK2-mediated neurodegenerative disease or disorder. In some embodiments, the TYK2- mediated disorder neuroinflammatory disease is, for example, multiple sclerosis.

Described herein are biomarkers for the prediction of the risk of developing and / or having multiple sclerosis (MS), as well as staging / subtyping MS and methods for evaluating treatment protocols for MS and for assisting in the prognosis of MS. Also described herein are biomarkers associated with multiple sclerosis (MS), particular GLX molecules, and even more particular GLX-related glycosaminoglycans (GAGs) and GLX-related proteoglycans (PGs).

The invention provides a method of detecting or predicting a relapse of multiple sclerosis in an individual having a form of multiple sclerosis, comprising: (a) providing a blood sample of the individual; (b) testing the blood sample to determine a protein activity or protein level, wherein the protein is Factor VIII, von Willebrand Factor, or Protein C; and (c) detecting or predicting a relapse of multiple sclerosis in the individual if the protein activity or protein level is elevated compared to the protein activity or protein level in an individual not having the form of multiple sclerosis and the patient's own baseline value. The invention also provides a method of treating an individual having multiple sclerosis who is experiencing a relapse or is predicted to experience a relapse, comprising treating the individual by administering a dose of a steroid or an anticoagulant compound effective to reduce symptoms of multiple sclerosis.

This description refers to the field of therapeutic tyrosine kinase inhibitors, in particular to Bruton's tyrosine kinase ("BTK") inhibitors for the treatment of subjects with relapsing multiple sclerosis.

The present invention relates to B-hydroxy and amino substituted carboxylic acide, which act as matrix metalloprotease inhibitor, particularly diastereomerically pure B-hydroxy carboxylic acid, corresponding processes for the synthesis of and pharmaceutical composition containing the compounds of the present invention. Compound of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriaasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compound.

The present invention relates to a sustained-release fampridine composition with high flowability and moisture control which can be used to treat individuals affected with multiple sclerosis and a preparation process thereof.

The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2 / DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.

This invention discloses a class of 3-substituted phthalide compounds (I) and their pharmaceutically acceptable salts, their preparation methods, pharmaceutical compositions, and their use in the preparation of drugs for the treatment and / or prevention of neurological diseases, including but not limited to vascular dementia, Alzheimer's disease, frontotemporal dementia, Prion's disease, Lewy body dementia, Parkinson's disease, Huntington's disease, HIV-related dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, ischemic stroke, hemorrhagic stroke, and neurological damage caused by traumatic brain injury;